In a 82-year-old female a 22-mm stented Soprano (Sorin Biomedica Cardio, Saluggia, Italy), bioprosthesis dysfunction was documented. Computed tomography angiography (CTA) showed diffuse aortic calcifications and the presence of an aberrant right subclavian artery or arteria lusoria (AL) ( Fig. 1A-D) . A valve-in-valve transcatheter aortic valve implantation (TAVI) with a 26-mm Corevalve Evolut R (Medtronic, Minneapolis, MN, USA) was performed via transfemoral access. Due to blood loss, CTA was required; aside a retroperitoneal hematoma, a large calcified plaque, previously undetected at the thoraco-abdominal passage was unexpectedly detected (Fig. 1E, F) , causing a 50% caliber reduction.
A careful review of a previous CTA suggested the migration of a voluminous calcification from the aortic arch, likely during system advancement.
Since the patient was asymptomatic, a conservative approach was recommended.
Six months later another CTA confirmed the entrapment of the calcified plaque in the descending aorta (Fig. 1G ) without clinical signs of peripheral hypoperfusion.
Systemic embolization during TAVI remains a major issue and the protective role of filters for cerebral protection is controversial. Peripheral embolization is considered a "minor" complication, and, in the described case, the dimension of plaque caused its entrapment without clinical consequences. Its fracture could have provoked migration toward more "sensible" districts, e.g. causing visceral or limb ischemia. With the exponential growth of TAVI, nowadays proposed also to treat younger patients and lower risk populations, a careful evaluation of the embolic risk and the development of dedicated algorithms should be advocated. 
